Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 4, 2016
Pharmacy Choice - News - Pharmaceutical Development - May 4, 2016

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/4/16 - ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11, 2016, at 2:20 p.m. Pacific Time
5/4/16 - Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
Actelion Pharmaceuticals Ltd/ Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland- All Board proposals approved. ALLSCHWIL/ BASEL, SWITZERLAND- 04 May 2016- At today's Annual General Meeting of Actelion Ltd, held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with a significant
5/4/16 - Alembic Pharma tumbles 2% despite FDA go-ahead for partial onset seizures drug [India Infoline News Service]
Shares of Alembic Pharma closed 1.59% lower at Rs. 593.30 on BSE after the company received USFDA's approval for partial onset seizures drug. The company has received final approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Lacosamide Tablets, SO mg, 100 mg, lSO mg and 200 mg.The approved ANDA is therapeut
5/4/16 - Angiochem Announces End-of-Phase 2 Meeting With FDA
Angiochem, a biotechnology company developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain metastases, announced today that the U.S. Food and Drug Administration has scheduled an End-of-Phase 2 meeting to discuss clinical study results of the compound. Angiochem submitted a meeting request to t
5/4/16 - Aridis Pharmaceuticals Strengthens Board of Directors with Former Wyeth now Pfizer President of R&D Robert Ruffolo, Jr.
Dr. Ruffolo is the retired President of Research and Development at Wyeth Pharmaceuticals, and retired Corporate Senior Vice President of Wyeth. Dr. Ruffolo brings substantial drug discovery and development expertise to Aridis. Prior to Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals where he was Senior Vice President and Di
5/4/16 - Audentes Therapeutics and the University of Pennsylvania Announce Collaboration to Develop AAV Gene Therapy for Severe Liver Disease
Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases, today announced a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania to develop AT342, an AAV gene...
5/4/16 - BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease [National News Agency (Lebanon)]
-BioMarin Pharmaceutical Inc. today announced that the European Medicines Agency has granted BioMarin's request for accelerated assessment for the planned cerliponase alfa Marketing Authorization Application. The company expects to submit the cerliponase alfa MAA to the EMA and the Biologics License Application to the U.S. Food and Drug...
5/4/16 - BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference
NESS ZIONA, Israel, May 4, 2016/ PRNewswire/. BiondVax Pharmaceuticals Ltd. announced today that BiondVax's CEO, Dr. Babecoff will be presenting at 10:30am at Pioneers 2016, a conference presented by Joseph Gunner& Co, taking place at the New York Palace Hotel.
5/4/16 - Collegium Announces Positive Topline Results of Comparative Clinical Trial Evaluating the Effect of Crushing Xtampza? ER Compared with OxyContin
Collegium Pharmaceutical, Inc. today announced positive topline results from a comparative clinical trial evaluating the effect of physical manipulation by crushing of Xtampza? ER compared with the abuse-deterrent version of OxyContin . Xtampza ER, Collegium s first FDA approved product utilizing its proprietary DETERx technology platfo
5/4/16 - Determination That LEUCOVORIN CALCIUM (Leucovorin Calcium) Injectable and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or...
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements. The 1984 amendments include what is now section 505 of
5/4/16 - DGAP-News: VAXIMM initiates Phase 2a study in advanced colorectal cancer with oral T-cell vaccine VXM01
DGAP-News: VAXIMM AG/ Key word: Study VAXIMM initiates Phase 2 a study in advanced colorectal cancer with oral T-cell vaccine VXM01 04.05. 2016/ 09:00 The issuer is solely responsible for the content of this announcement.- VAXIMM initiates Phase 2 a study in advanced colorect
5/4/16 - Eli Lilly: FDA Grants Priority Review For Olaratumab
INDIANAPOLIS- Eli Lilly and Company announced the U.S. FDA has granted Priority Review for the biologics license application for olaratumab, a PDGFR? The company has received additional designations for olaratumab from the FDA, including Breakthrough Therapy, Fast Track and Orphan Drug, for this indication. Lilly also submitted olaratumab to the Eu
5/4/16 - Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
Elite Pharmaceuticals, Inc. announced today that its Board of Directors has appointed Davis S. Caskey to its board effective April 28, 2016.. From 1990 until 2013, Mr. Caskey was employed by ECR Pharmaceuticals Co., Inc., a venture that was founded in 1990 and acquired by Hi-Tech Pharmacal in March 2009, where he served as the operating officer.
5/4/16 - Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma
Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the U.S. Food and Drug Administration has accepted the company s Investigational New Drug application for tazemetostat for the treatment of adults with mesothelioma characterized by BAP1 loss-of-function.
5/4/16 - EVOK Expects Data In Q3, PRTA Has Its Hands Full, SUPN Awaits FDA Decision
DUBLIN- BioMarin Pharmaceutical Inc. expects to submit EU and U.S. Marketing Application for Cerliponase alfa, intended for the treatment of children with CLN2 disease, a form of Batten disease, by mid-2016. In just another two months, Corcept Therapeutics Inc. will be reporting results from a phase 1/ 2 trial of mifepristone in combination with an
5/4/16 - Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 [Daily Star, The (Lebanon)]
-Evoke Pharma, Inc. today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of 2016. Dave Gonyer, R.Ph., President and CEO stated, Having completed enrollment in our pivotal Phase 3 trial of EVK-001, w
5/4/16 - FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma
Eli Lilly and Company announced today that the U.S. Food and Drug Administration has granted Priority Review for the biologics license application for olaratumab, a PDGFR antagonist, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma not amenable to curative treatment with radiotherapy or su
5/4/16 - Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea [Seven Days (United Arab Emirates)]
-Foamix Pharmaceuticals Ltd.,, a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced the completion of enrollment in a Phase 2 clinical trial of FMX103 for the treatment of papulopustular rosacea. It affects more than 16 million people i
5/4/16 - GNW-News: Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved (english)
Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland- All Board proposals approved. Actelion Pharmaceuticals Ltd/ Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland- All Board proposals approved. ALLSCHWIL/ BASEL, SWITZERLAND- 04 May 2016- At today's Annual General Meeting of Actelion Ltd, held in B
5/4/16 - GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016,
5/4/16 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 13796) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss new drug application 208653, benzhydrocodone/acetaminophen oral tablets, submitted by KemPharm, Inc., with the proposed...
5/4/16 - Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Three Additional Notices of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2% w/w
Horizon Pharma plc, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it received three additional Notice of Allowances from the United States Patent and Trademark Office for U.S. patent.
5/4/16 - Intec Pharma Appoints VP of Clinical and Regulatory Affairs [Global Data Point]
Strauss-Levy has 15 years of experience in clinical research and regulatory affairs, and has established an outstanding track record, having supported the advancement of several products through the clinical development and regulatory approval processes in the United States and Europe, including several Phase III clinical trials, "said Zeev Weiss,
5/4/16 - Ionis Reports Financial Results and Highlights for First Quarter 2016
Ionis Pharmaceuticals, Inc. today reported its financial results for the first quarter were in line with the company's expectations. We are actively engaged in NDA preparations for all three of these drugs in anticipation of Phase 3 data from each in the first half of next year, "said B. Lynne Parshall, chief operating officer of Ionis Pharmaceut
5/4/16 - Juniper Pharmaceuticals Reports First Quarter 2016 Financial Results
Juniper Pharmaceuticals, Inc., a women's health therapeutics company, today announced financial results for the three-month period ended March 31, 2016. Phase 2 b trial of COL-1077 10% lidocaine vaginal gel in women undergoing a minimally invasive pipelle-directed endometrial biopsy on track for Q3 2016 data readout; Pre-IND meeting with the U.S.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415